Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid ar… Read more
Voronoi Co. Ltd. (310210) - Net Assets
Latest net assets as of September 2025: ₩53.21 Billion KRW
Based on the latest financial reports, Voronoi Co. Ltd. (310210) has net assets worth ₩53.21 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩99.56 Billion) and total liabilities (₩46.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩53.21 Billion |
| % of Total Assets | 53.44% |
| Annual Growth Rate | 36.91% |
| 5-Year Change | 136.39% |
| 10-Year Change | N/A |
| Growth Volatility | 163.07 |
Voronoi Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Voronoi Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Voronoi Co. Ltd. (2019–2024)
The table below shows the annual net assets of Voronoi Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩66.41 Billion | -18.36% |
| 2023-12-31 | ₩81.34 Billion | +137.44% |
| 2022-12-31 | ₩34.26 Billion | +395.19% |
| 2021-12-31 | ₩6.92 Billion | -75.38% |
| 2020-12-31 | ₩28.09 Billion | +103.63% |
| 2019-12-31 | ₩13.80 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Voronoi Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12764481054000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩9.18 Billion | 13.83% |
| Other Components | ₩246.74 Billion | 371.53% |
| Total Equity | ₩66.41 Billion | 100.00% |
Voronoi Co. Ltd. Competitors by Market Cap
The table below lists competitors of Voronoi Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bangkok Expressway and Metro Public Company Limited
PINK:BKKXF
|
$2.46 Billion |
|
First Capital Real Estate Investment Trust
PINK:FCXXF
|
$2.46 Billion |
|
Dana Inc
NYSE:DAN
|
$2.46 Billion |
|
Engie Brasil Energia SA
PINK:EGIEY
|
$2.47 Billion |
|
SOCNF
PINK:SOCNF
|
$2.45 Billion |
|
The Unite Group plc
F:U1B
|
$2.45 Billion |
|
BancFirst Corporation
NASDAQ:BANF
|
$2.45 Billion |
|
Privia Health Group Inc
NASDAQ:PRVA
|
$2.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Voronoi Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 81,343,825,340 to 66,412,537,870, a change of -14,931,287,470 (-18.4%).
- Net loss of 32,613,098,090 reduced equity.
- Share repurchases of 4,742,124,160 reduced equity.
- New share issuances of 4,742,124,160 increased equity.
- Other factors increased equity by 17,681,810,620.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-32.61 Billion | -49.11% |
| Share Repurchases | ₩4.74 Billion | -7.14% |
| Share Issuances | ₩4.74 Billion | +7.14% |
| Other Changes | ₩17.68 Billion | +26.62% |
| Total Change | ₩- | -18.36% |
Book Value vs Market Value Analysis
This analysis compares Voronoi Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 93.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 307.82x to 93.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩1127.29 | ₩347000.00 | x |
| 2020-12-31 | ₩2260.87 | ₩347000.00 | x |
| 2021-12-31 | ₩556.72 | ₩347000.00 | x |
| 2022-12-31 | ₩2295.71 | ₩347000.00 | x |
| 2023-12-31 | ₩4786.22 | ₩347000.00 | x |
| 2024-12-31 | ₩3696.48 | ₩347000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Voronoi Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-49.11%) is above the historical average (-135.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -362.42% | -16627.54% | 0.01x | 2.22x | ₩-51.38 Billion |
| 2020 | -82.53% | -375.20% | 0.13x | 1.70x | ₩-26.00 Billion |
| 2021 | -218.21% | -102.11% | 0.37x | 5.81x | ₩-15.79 Billion |
| 2022 | -58.09% | -203.73% | 0.15x | 1.87x | ₩-23.33 Billion |
| 2023 | -45.30% | 0.00% | 0.00x | 1.16x | ₩-44.98 Billion |
| 2024 | -49.11% | 0.00% | 0.00x | 1.11x | ₩-39.25 Billion |
Industry Comparison
This section compares Voronoi Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Voronoi Co. Ltd. (310210) | ₩53.21 Billion | -362.42% | 0.87x | $2.46 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |